102 related articles for article (PubMed ID: 27531787)
41. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
42. Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.
Tati R; Kristoffersson AC; Manea Hedström M; Mörgelin M; Wieslander J; van Kooten C; Karpman D
EBioMedicine; 2017 Feb; 16():302-311. PubMed ID: 28139439
[TBL] [Abstract][Full Text] [Related]
43. Changes in plasma von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina.
Fuchigami S; Kaikita K; Soejima K; Matsukawa M; Honda T; Tsujita K; Nagayoshi Y; Kojima S; Nakagaki T; Sugiyama S; Ogawa H
Thromb Res; 2008; 122(5):618-23. PubMed ID: 18295305
[TBL] [Abstract][Full Text] [Related]
44. Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation.
Uemura T; Kaikita K; Yamabe H; Soejima K; Matsukawa M; Fuchigami S; Tanaka Y; Morihisa K; Enomoto K; Sumida H; Sugiyama S; Ogawa H
Thromb Res; 2009 May; 124(1):28-32. PubMed ID: 18996572
[TBL] [Abstract][Full Text] [Related]
45. Update on ADAMTS13 and VWF in cardiovascular and hematological disorders.
Akyol O; Akyol S; Chen CH
Clin Chim Acta; 2016 Dec; 463():109-118. PubMed ID: 27746209
[TBL] [Abstract][Full Text] [Related]
46. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F
Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645
[TBL] [Abstract][Full Text] [Related]
47. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease.
Miura M; Kaikita K; Matsukawa M; Soejima K; Fuchigami S; Miyazaki Y; Ono T; Uemura T; Tsujita K; Hokimoto S; Sumida H; Sugiyama S; Matsui K; Yamabe H; Ogawa H
Thromb Haemost; 2010 Mar; 103(3):623-9. PubMed ID: 20135067
[TBL] [Abstract][Full Text] [Related]
48. ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition.
Bockmeyer CL; Reuken PA; Simon TP; Budde U; Lösche W; Bauer M; Birschmann I; Becker JU; Marx G; Claus RA
Thromb Haemost; 2011 Jan; 105(1):145-53. PubMed ID: 21057705
[TBL] [Abstract][Full Text] [Related]
49. ADAMTS13 related markers and von Willebrand factor in plasma from patients with thrombotic microangiopathy (TMA).
Kobayashi T; Wada H; Nishioka N; Yamamoto M; Matsumoto T; Tamaru T; Nomura S; Masuya M; Mori Y; Nakatani K; Nishikawa M; Katayama N; Nobori T
Thromb Res; 2008; 121(6):849-54. PubMed ID: 17900666
[TBL] [Abstract][Full Text] [Related]
50. Platelet-free shear flow assay facilitates analysis of shear-dependent functions of VWF and ADAMTS13.
Kraus E; Kraus K; Obser T; Oyen F; Klemm U; Schneppenheim R; Brehm MA
Thromb Res; 2014 Dec; 134(6):1285-91. PubMed ID: 25201004
[TBL] [Abstract][Full Text] [Related]
51. Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation.
Freynhofer MK; Bruno V; Jarai R; Gruber S; Höchtl T; Brozovic I; Farhan S; Wojta J; Huber K
Thromb Haemost; 2011 Mar; 105(3):435-43. PubMed ID: 21136020
[TBL] [Abstract][Full Text] [Related]
52. The Role of von Willebrand Factor, ADAMTS13, and Cerebral Artery Thrombus Composition in Patient Outcome Following Mechanical Thrombectomy for Acute Ischemic Stroke.
Prochazka V; Jonszta T; Czerny D; Krajca J; Roubec M; Macak J; Kovar P; Kovarova P; Pulcer M; Zoubkova R; Lochman I; Svachova V; Pavliska L; Vrtkova A; Kasprak D; Gumulec J; Weisel JW
Med Sci Monit; 2018 Jun; 24():3929-3945. PubMed ID: 29887594
[TBL] [Abstract][Full Text] [Related]
53. [ADAMTS13, von Willebrand factor specific cleaving protease].
Veyradier A; Coppo P
Med Sci (Paris); 2011 Dec; 27(12):1097-105. PubMed ID: 22192749
[TBL] [Abstract][Full Text] [Related]
54. ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment.
Hori Y; Hayakawa M; Isonishi A; Soejima K; Matsumoto M; Fujimura Y
Transfusion; 2013 Dec; 53(12):3192-202. PubMed ID: 23560518
[TBL] [Abstract][Full Text] [Related]
55. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Shelat SG; Ai J; Zheng XL
Semin Thromb Hemost; 2005 Dec; 31(6):659-72. PubMed ID: 16388417
[TBL] [Abstract][Full Text] [Related]
56. Von Willebrand factor, its cleaving protease (ADAMTS13), and inflammation in young adults: The African-PREDICT study.
Möller C; Schutte AE; Smith W; Botha-Le Roux S
Cytokine; 2020 Dec; 136():155265. PubMed ID: 32927287
[TBL] [Abstract][Full Text] [Related]
57. Von Willebrand factor, ADAMTS13 activity, TNF-α and their relationships in patients with chronic kidney disease.
Shen L; Lu G; Dong N; Jiang L; Ma Z; Ruan C
Exp Ther Med; 2012 Mar; 3(3):530-534. PubMed ID: 22969924
[TBL] [Abstract][Full Text] [Related]
58. Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full term neonates.
Strauss T; Elisha N; Ravid B; Rosenberg N; Lubetsky A; Levy-Mendelovich S; Morag I; Nowak Göttl U; Kenet G
Blood Cells Mol Dis; 2017 Sep; 67():14-17. PubMed ID: 28087247
[TBL] [Abstract][Full Text] [Related]
59. Highly elevated plasma level of von Willebrand factor accelerates the formation of platelet thrombus under high shear stress in plasma with deficient ADAMTS13 activity.
Yagi H; Yamaguchi N; Shida Y; Sugimoto M; Tubaki K; Fujimura Y; Matsumoto M
Thromb Res; 2017 Nov; 159():91-95. PubMed ID: 29040872
[TBL] [Abstract][Full Text] [Related]
60. Mutations and Common Polymorphisms in ADAMTS13 and vWF Genes Responsible for Increasing Risk of Thrombosis.
Haybar H; Khodadi E; Kavianpour M; Saki N
Cardiovasc Hematol Disord Drug Targets; 2018; 18(3):176-181. PubMed ID: 29669506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
